FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other Events

FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On May 21, 2018, the Company issued a press release announcing interim results and progress of its Phase 1/2 clinical trial of FCX-007. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.

Description

Press Release dated May 21, 2018.


Fibrocell Science, Inc. Exhibit
EX-99.1 2 a052118finalfcscfcx007v9.htm EXHIBIT 99.1 a052118finalfcscfcx007v9 Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa – FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals,…
To view the full exhibit click here

About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

An ad to help with our costs